IVIRMA Global Has Helped More Than 220,000 Babies Come into the World
In November 2023, IVIRMA acquired Eugin Group for up to EUR 500 million. In January 2025, it added three Southern California clinics. In November 2025, it established a Middle East presence by acquiring ART Fertility Clinics in the UAE and Saudi Arabia. In a surrogacy market growing at 24.14% annually toward USD 145.21 billion, IVIRMA is not building a fertility network. It is building the fertility infrastructure of the next generation.
There is a moment in fertility medicine that most statistics cannot capture. It is the moment a surrogate and a set of intended parents first hear a heartbeat on an ultrasound, after months of IVF cycles, embryo transfers, legal agreements, and medical monitoring across multiple countries.
IVIRMA Global has been present at more than 220,000 of those moments.
The Spain-founded fertility and reproductive medicine group – with over 4,400 employees operating across more than 190 locations in 14 countries – has spent three decades building the world’s largest evidence-based fertility network. And in the period between November 2023 and November 2025, it executed the most commercially ambitious acquisition sequence in its history.
The Global Surrogacy Market was valued at USD 25.74 billion in 2024 and is projected to reach USD 145.21 billion by 2032, growing at a CAGR of 24.14%, per Maximize Market Research. IVIRMA sits at the center of every force driving that growth: rising global infertility rates, aging populations delaying parenthood, expanding LGBTQ+ family-building, cross-border fertility services, and the application of AI to IVF embryo selection.
Three Acquisitions in Two Years: Building the Global Surrogacy Infrastructure
IVIRMA’s acquisition sequence between late 2023 and late 2025 is remarkable in both pace and geographic ambition:
- November 2023 – Eugin Group (EUR 500 million): IVIRMA, alongside Spanish investment firm GED Capital, acquired Barcelona-based Eugin Group – one of Europe’s largest fertility clinic networks – in a deal valued at up to EUR 500 million including earn-outs. The acquisition added significant European clinical capacity and pooled embryo data that can be used to train AI-driven embryo selection algorithms across a larger patient base.
- January 2025 – Southern California Expansion: IVI RMA North America acquired Reproductive Health and Wellness Center, Rise Fertility, and Halo Fertility from Global Premier Fertility in Southern California. The acquisition extended IVIRMA’s North American footprint along the U.S. Pacific Coast, a geography with high concentrations of intended parents and gestational surrogates.
- November 2025 – ART Fertility Clinics (UAE and Saudi Arabia): IVIRMA established the Middle East as its fifth global region by acquiring ART Fertility Clinics – a leading reproductive medicine group founded in 2015, with state-of-the-art facilities in the UAE and Saudi Arabia. The deal was valued at approximately USD 264 million.
MMR Insight: IVIRMA’s acquisition strategy is clinically coherent, not just commercially opportune. Every new clinic network adds to a shared embryo outcome database that is being used to train AI embryo selection systems. The more patient data IVIRMA accumulates across its global network, the more accurate its AI-assisted IVF outcomes become – creating a data flywheel that smaller independent clinics cannot replicate.
The IVF Technology That Makes IVIRMA’s Scale Commercially Decisive
Fertility centers held 72.86% of the global surrogacy market’s revenues in 2025, according to industry analysis, because they provide the integrated medical teams, embryology laboratories, and genetic testing capabilities that surrogacy arrangements depend on.
IVIRMA’s North American network alone – comprising Reproductive Medicine Associates, Boston IVF, Toronto-based TRIO, and Pearl Mini-IVF – spans 22 IVF laboratories and has published over 1,000 peer-reviewed research papers. Its academic affiliations include Harvard Medical School, Dartmouth Hitchcock Medical School, Boston University Medical Center, and Tufts Medical Center – institutions that provide ongoing clinical validation for IVIRMA’s protocols and attract research funding that benefits every patient in the network.
IVIRMA also partnered with Gaia in June 2025 to deliver value-based fertility care, expanding financial access to surrogacy and IVF services for patients who cannot meet the upfront cost requirements of conventional clinic fee structures.
Final Take
The global surrogacy market’s 24.14% CAGR is one of the highest sustained growth rates in any healthcare segment globally. That growth is being driven by a convergence of demographic, social, and technological forces that will not reverse.
IVIRMA is building the infrastructure to capture that growth across five continents, with a data network, research base, and clinical expertise that compounds with every acquisition it completes. In a market heading toward USD 145.21 billion by 2032, the fertility group that controls the most clinics, the most patient data, and the most rigorous IVF science will write the outcome metrics the rest of the industry is measured against.
Related Reports
Explore related market intelligence reports from Maximize Market Research: